Alzamend Neuro FY26 net loss widens 94% to $8.77 million

Reuters2026/07/22 20:39

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alzamend Neuro posted a GAAP net loss of USD 8.77 million, widening 94% from the prior fiscal year.
Operating loss widened 95% to USD 8.77 million as operating expenses climbed 95% to USD 8.77 million.
Research and development expense more than doubled to USD 3.63 million, driven by clinical trial fees of USD 2.93 million.
General and administrative costs rose 67% to USD 5.14 million on higher professional fees of USD 2.18 million, including USD 1.9 million in legal fees.
Cash was USD 711,000 at April 30, 2026; management flagged substantial doubt about going-concern status within one year of issuance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-008832), on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alzamend Neuro FY26 net loss widens 94% to $8.77 million

You may also like

Crypto prices